人福医药：九珑人福“盐酸达泊西汀片”取得注册证

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval for the drug "Dapoxetine Hydrochloride Tablets" from the National Medical Products Administration [1] - The revenue composition for Renfu Pharmaceutical in 2024 is projected to be 56.01% from pharmaceuticals, 43.8% from pharmaceutical wholesale and related businesses, and 0.19% from other businesses [1] - As of the report, Renfu Pharmaceutical has a market capitalization of 34.4 billion yuan [1]